ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

De Novo Dosing and Trough Attainment Trends of Extended-Release Tacrolimus in the Absence of Dose Adjustments

M. J. Moritz1, D. R. Stevens2, U. Meier-Kriesche2, T. A. Horwedel2

1Department of Surgery, Lehigh Valley Health Network, Allentown, PA, 2Veloxis Pharmaceuticals, Cary, NC

Meeting: 2020 American Transplant Congress

Abstract number: D-101

Keywords: Dosage, Immunosuppression

Session Information

Session Name: Poster Session D: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Initial dosing of tacrolimus extended-release tablets (LCPT) was 0.17 mg/kg/day in the pivotal trial in de novo kidney transplant recipients. Dosing subsequent to the first dose was based on clinician assessment of troughs. Most patients’ trough concentrations were above the protocol-specific target leading to frequent dose changes, which makes interpretation of early assessment of this dosing strategy difficult. To better understand trends in early levels in the absence of dose changes, we performed a post-hoc, subgroup analysis of patients who did not receive a dose change in the first 7 days following initiation of LCPT therapy at 0.17 mg/kg/day.

*Methods: Patients randomized to receive LCPT were included in this analysis if they remained in the study and had no dosage adjustments through the first 7 days post-initiation of tacrolimus therapy. The primary outcome was median level at each timepoint through the first week. Secondary outcomes include median dose and level through the first 14 post-initiation days.

*Results: In total, 39 patients met inclusion for this analysis. Demographics and transplant characteristics are noted below.

Table 1. Patient Characteristics
Full Study  cohort (N=268) No dose adjustment cohort (N=39)
Age (mean) 44.8 39.9
Male sex (%) 64.9 56.4
Caucasian Race (%) 75.7 82.1
Weight, Kg 74.9 68.0
Deceased donor (%) 49.6 51.3
Prior transplant (%) 4.1 10.3
Low CD Ratio (%) 33.3 50.3

A previous analysis of the full study population classified patients into trough concentration to dose (CD) ratio tertiles based on day 30 dose and trough; using this scheme, the majority of patients who did not require dose adjustments fell into the low CD ratio category, indicating that these patients would likely require higher doses to maintain therapeutic levels, on average. Average trough levels are shown.

 border=

Study defined goal was between 6 – 11 ng/mL for the first 30 days. Trough concentrations gradually increased over the first week. After 7 days, the LCPT dose among this cohort was reduced from the starting dose of 0.17 mg/kg to 0.15 mg/kg to maintain therapeutic levels.

*Conclusions: These results illustrate trough level attainment trends in the first week post-transplant utilizing LCPT. It appears that gradual increases in the mean tacrolimus trough occur throughout the first 7 days.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Moritz MJ, Stevens DR, Meier-Kriesche U, Horwedel TA. De Novo Dosing and Trough Attainment Trends of Extended-Release Tacrolimus in the Absence of Dose Adjustments [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/de-novo-dosing-and-trough-attainment-trends-of-extended-release-tacrolimus-in-the-absence-of-dose-adjustments/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences